Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) trading at $5.94 after decrease. On Apr, 15 the move was announced by Barchart.com. The company has $148.50 million MC. The valuation of NASDAQ:SNDX can change by $10.40M if our $5.52 target is hit.

For more Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) news released recently go to: Seekingalpha.com, Benzinga.com, Nasdaq.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “CorMedix and WellCare Health Plans among healthcare gainers; Moleculin Biotech leads the losers – Seeking Alpha” released on March 27, 2019, “50 Biggest Movers From Yesterday – Benzinga” on April 12, 2019, “Mid-Day Market Update: Crude Oil Down Over 1%; Syndax Pharmaceuticals Shares Spike Higher – Nasdaq” with a publish date: March 27, 2019, “46 Biggest Movers From Yesterday – Benzinga” and the last “Syndax Pharmaceuticals (SNDX) Investor Presentation – Slideshow – Seeking Alpha” with publication date: March 14, 2019.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications.The firm is worth $148.50 million. The companyÂ’s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial.Last it reported negative earnings. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity.